Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-13
2007-03-13
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S183000, C514S311000, C514S312000, C514S313000
Reexamination Certificate
active
10374644
ABSTRACT:
This invention provides the use of CCI-779 in the treatment of neoplasms.
REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3993749 (1976-11-01), Sehgal et al.
patent: 4401653 (1983-08-01), Eng
patent: 4885171 (1989-12-01), Surendra et al.
patent: 5078999 (1992-01-01), Warner et al.
patent: 5080899 (1992-01-01), Sturm et al.
patent: 5100899 (1992-03-01), Calne
patent: 5206018 (1993-04-01), Sehgal et al.
patent: 5286730 (1994-02-01), Caufield et al.
patent: 5286731 (1994-02-01), Caufield et al.
patent: 5288711 (1994-02-01), Mitchell et al.
patent: 5321009 (1994-06-01), Baeder et al.
patent: 5362718 (1994-11-01), Skotnicki et al.
patent: 5387589 (1995-02-01), Kulkarni
patent: 5496832 (1996-03-01), Armstrong
patent: 5516781 (1996-05-01), Morris et al.
patent: 5561138 (1996-10-01), Armstrong
patent: 5728710 (1998-03-01), Luengo
patent: 6617333 (2003-09-01), Rabindran et al.
patent: 2002/0183239 (2002-12-01), Gibbons, Jr.
patent: 2002/0183240 (2002-12-01), Gibbons, Jr.
patent: 0 525 960 (1993-02-01), None
Carter et al., Chemotherapy of Cancer, second edition, John Wiley & Sons, N.Y., N.Y., 1981, pp. 362-365.
Geoerger, B. et al., Cancer Research, vol. 61, No. 4, Feb. 15, 2001, pp. 1527-1532.
Schwartsmann, G. et al., Annals of Oncology, vol. 11, No. 3, Oct. 13, 2000, pp. 235-243.
S.N. Sehgal et al., J. Antibiot., 1975, 727, 28.
C.V. Vezina et al., J. Antibiot., 1975, 721, 28.
H.A. Baker et al., J. Antibiot., 1978, 539, 31.
FASEB, 1989, 3411, 3.
FASEB, 1989, 5256, 3.
R.Y. Calne et al., Lancet, 1978, 1183.
R. Martel et al., Can. J. Physiol. Pharmacol., 1977, 48, 55.
J. Alexandre et al., Bull. Cancer, 1999, 808, 86.
A. Perren et al., Am. J. Pathology, 1999, 1253, 155.
J.E. Dancey et al., ASCO Educational Book, Spring 2000, 68.
M. Hidalgo et al., Oncogene, 2000, 6680, 19.
E.A. Sausvile et al., ASCO Educational Book, Fall 1998, 112.
T. Schmelzle et al., Cell, 2000, 253, 103.
J. Alexandre et al., “CCI-779, a new rapamycin analog, has antitumor activity at doses inducing only mild cutaneous effects and mucositis; early results of an ongoing phase 1 study”, Proceedings of the 10thNCI/EORTC/AACR Symposium, 1999 (poster presentation).
J.J. Gibbons et al., Proceedings of the American Association for Cancer Research, 1999, 301a, 40.
B: Geoerger et al., Proceedings of the American Association for Cancer Research, 1999, 603a, 40.
J. Alexandre et al., Proceedings of the American Association for Cancer Research, 2000, 613, 41.
M. Hidalgo et al., Proceedings of the 11thNCI/EORTC/AACR Symposium, 2000, 4548s, 6 (Supp.).
M. Hidalgo et al., Annals of Oncology, 2000, 133a, 11(4).
E. Raymond et al., Proceedings of the 11thNCI/EORTC/AACR Symposium, 2000, Ab. 414.
E. Raymond et al., Proceedings of ASCO, 2000, 187a, 19.
M. Hidalgo, “Phase 1 and Pharmacological Studies with the Rapamycin Analog CCI-779 Administered as a 30 Minute Infusion”, NCI-CTEP Drug Development Meeting, Oct. 1999.
M. Abou-Gharbia, “Medicinal Chemistry Approaches for Optimization of Early Leads in Drug Candidates: The Discovery of Calicheamicin, Rapamycin and EAA-090”, International Conference on Pure and Applied Heterocyclic Chemistry, Mar. 2000.
R. Langreth et al., The Wall Street Journal, Nov. 17, 1999, vol. 234.
Alberts, New Perspectives on a1 Old Friend: optimizing carboplatin for the treatment of solid tumors, Oncologist, 3(1), pp. 15-34, (1998) ABSTRACT.
Dorland's Illustrated Medical Dictionary, 24thEdition, p. 987, 1965.
Peter Robins, Poster Highlights 1, IDrugs, vol. 2, No. 6, Paragraph, CCI-779, (1999) XP-001083882.
Discafani-Marro Carolyn M
Dukart Gary
Frost Philip
Gibbons, Jr. James J
Speicher Lisa A
Anderson James D.
Howson & Howson LLP
Marschel Ardin H.
Milowsky Arnie S.
Wyeth
LandOfFree
Use of CCI-779 as an antineoplastic agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of CCI-779 as an antineoplastic agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of CCI-779 as an antineoplastic agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3775802